Simcere Zaiming will present 7 innovative researches at the 2025 AACR
Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA
NDA of Deunoxavir Marboxil ,the Next Generation Innovative Influenza Drug get Accepted , Offering Hope for "One-Pill Cure" for Influenza.
All Patients Enrolled in Phase III Clinical Study of Deunoxavir Marboxil for Pediatric Indication
Simcere Pharmaceutical and Fermion Technology Collaborate to Develop China's First SSTR4-Targeting Analgesic
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SIM0505, an ADC candidates Simcere Zaiming developed using proprietary technology platform, is entering trials both in China and the USA
COSELA and Enlituo, two of Simcere Zaiming’ innovative product included in National Medical Insurance Catalogue
China NMPA approves Simcere’s Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
First Patient Enrolled in Phase III Clinical Trial of Deunoxavir Marboxil (An Innovative Anti-Influenza Drug) for Pediatric Indication